174 related articles for article (PubMed ID: 33001014)
1. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
Lingasamy P; Laarmann AH; Teesalu T
Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
[TBL] [Abstract][Full Text] [Related]
2. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
3. Tumor-penetrating peptide for systemic targeting of Tenascin-C.
Lingasamy P; Tobi A; Kurm K; Kopanchuk S; Sudakov A; Salumäe M; Rätsep T; Asser T; Bjerkvig R; Teesalu T
Sci Rep; 2020 Apr; 10(1):5809. PubMed ID: 32242067
[TBL] [Abstract][Full Text] [Related]
4. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.
Yagolovich AV; Isakova AA; Artykov AA; Vorontsova YV; Mazur DV; Antipova NV; Pavlyukov MS; Shakhparonov MI; Gileva AM; Markvicheva EA; Plotnikova EA; Pankratov AA; Kirpichnikov MP; Gasparian ME; Dolgikh DA
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293545
[TBL] [Abstract][Full Text] [Related]
5. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
[TBL] [Abstract][Full Text] [Related]
6. Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment.
Kang T; Zhu Q; Jiang D; Feng X; Feng J; Jiang T; Yao J; Jing Y; Song Q; Jiang X; Gao X; Chen J
Biomaterials; 2016 Sep; 101():60-75. PubMed ID: 27267628
[TBL] [Abstract][Full Text] [Related]
7. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
[TBL] [Abstract][Full Text] [Related]
8. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
[TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.
Silacci M; Brack SS; Späth N; Buck A; Hillinger S; Arni S; Weder W; Zardi L; Neri D
Protein Eng Des Sel; 2006 Oct; 19(10):471-8. PubMed ID: 16928692
[TBL] [Abstract][Full Text] [Related]
10. Clinical advances in TNC delivery vectors and their conjugate agents.
Chen W; Wu Y; Wang J; Yu W; Shen X; Zhao K; Liang B; Hu X; Wang S; Jiang H; Liu X; Zhang M; Xing X; Wang C; Xing D
Pharmacol Ther; 2024 Jan; 253():108577. PubMed ID: 38081519
[TBL] [Abstract][Full Text] [Related]
11. Increased antitumor activity of tumor-specific peptide modified thymopentin.
Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
[TBL] [Abstract][Full Text] [Related]
12. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy.
Song Y; Xu M; Li Y; Li Y; Gu W; Halimu G; Fu X; Zhang H; Zhang C
Int J Pharm; 2020 Aug; 586():119498. PubMed ID: 32505575
[TBL] [Abstract][Full Text] [Related]
13. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
14. Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery.
Lingasamy P; Tobi A; Haugas M; Hunt H; Paiste P; Asser T; Rätsep T; Kotamraju VR; Bjerkvig R; Teesalu T
Biomaterials; 2019 Oct; 219():119373. PubMed ID: 31374479
[TBL] [Abstract][Full Text] [Related]
15. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.
Lao X; Liu M; Chen J; Zheng H
PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.
Hu C; Chen X; Huang Y; Chen Y
Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568
[TBL] [Abstract][Full Text] [Related]
17. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide.
E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M
Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024
[TBL] [Abstract][Full Text] [Related]
18. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
19. Toward in vivo imaging of heart disease using a radiolabeled single-chain Fv fragment targeting tenascin-C.
Kobayashi N; Odaka K; Uehara T; Imanaka-Yoshida K; Kato Y; Oyama H; Tadokoro H; Akizawa H; Tanada S; Hiroe M; Fukumura T; Komuro I; Arano Y; Yoshida T; Irie T
Anal Chem; 2011 Dec; 83(23):9123-30. PubMed ID: 22074352
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
